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ABSTRACT
This study determined the effects of cumulative exposure to painful needle procedures and sucrose anal-
gesia on the development of remote hyperalgesia in newborn infants, defined as an increase in response
to a normally painful stimulus at a site distal from the site of injury. One-hundred and twenty healthy
newborns and 120 healthy newborn infants ofdiabetic mothers equally randomized to sucrose analgesia
or placebo prior to all needle procedures in the first two days after birth were divided into two exposure
groups according to number of needle procedures they had undergone [high ( 25) or low (g4)] using the
median cut-offtechnique. Compared to the low exposure group, infants in the high exposure group had a
higher pain response during a subsequent venipuncture distal to the site ofprevious injury, assessed by
the Premature Infant Pain Profile (PIPP) [7.1 vs. 8.4; p = O.O12l and Visual Analog Scale (VAS) [2.5 cm vs.
3.2 cm; p = g.g47l, and a trend for longer cry duration [25.7 s vs. 33.8 s; p = 6.171 ]. PIPP scores did not
differ during a routine diaper change, suggesting a nociceptive specific mechanism for the remote hyper-
algesia to venipuncture. Sucrose reduced PIPP, VAS, and cry duration scores during venipuncture, but did
not prevent hyperalgesia (p > 0.05). There was a preponderance of infants of diabetic mothers in the high
exposure group; however, the analysis did not demonstrate this to be a confounding factor. In conclusion,
sucrose analgesia for repeated painful procedures in the first day of life does not prevent development of
remote hyperalgesia in newborns.
1. Introduction
Newborn infants are subjected to procedural pain as part ofrou-
tine medical care. Untreated procedural pain can lead to profound
adverse effects. We previously demonstrated that newborn infants
born to mothers with diabetes and who underwent repeated heel
lances in the first 24-36h of life exhibited hyperalgesia (an in-
creased response to a stimulus which is normally painful) during
a subsequent venipuncture compared to normal infants who had
not undergone repeated painful procedures [25]. Other studies
have demonstrated that injury during infancy has local and global
consequences on sensory processing that can be observed years la-
ter [16].
A significant percentage of newborn infants are subjected to re-
peated procedural pain. Infants of diabetic mothers (lDMs) alone
constitute approximately 5% of live births [18]. An additional 10-
15% of newborns require prolonged hospitalization after delivery
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for medical reasons including prematurity, congenital anomalies,
sepsis, hyperbilirubinemia and feeding difficulties [13]. Individu-
ally, these infants may be exposed to up to hundreds of painful
procedures [9]. Reducing the burden of pain from medical
procedures in newbom infants is therefore clinically important
14.s1.
Sucrose (table sugar) is a naturally occurring sweetener with
analgesic effects in young infants. Although not fully understood,
the mechanism of action is postulated to involve activation of
the endogenous opioid system through taste [71. This is supported
by the presence ofopioid receptors on the tongue and animal stud-
ies demonstrating opioid-antagonist reversible analgesia during
noxious stimulation [19]. Moreover, chronic consumption of
sweeteners has been shown to negate the analgesic effects of opi-
oids [14].
Sucrose has been promoted for analgesia in clinical practice
guidelines and consensus statements based on systematic reviews
demonstrating its efficacy for common medical procedures such as
heel lance and venipuncture [2,3,8,21,22]. There is a lack of data,
however, on the effects of repeated doses. Specifically, it is unclear
whether consistent management of pain with sucrose prevents the
development ofexaggerated pain responses in the future in infants
who undergo repeated procedures.
This study was undertaken to determine the potential effects of:
(i) cumulative exposure to painful medical procedures, and (ii)
consistent management of procedural pain with sucrose, on the
development of remote hyperalgesia in newborn infants in the first
two days of life. The specific objectives were to determine the ef-
fects of exposure to a high vs. low number of painful procedures
and administration of sucrose vs. placebo on the subsequent devel-
opment of remote hyperalgesia, defined as an increase in response
to a venipuncture performed in uninjured skin on the dorsum of
the hand.
2- Materials and methods
We studied newborn infants >36 weeks gestational age at birth
that were enrolled in a double-blind randomized controlled trial of
the effectiveness of oral sucrose administered prior to every nox-
ious medical procedure performed after birth [26]. In order to en-
sure inclusion of infants undergoing a wide range in number of
medical procedures, we targeted normal newborn infants (born
of women with uneventful pregnancies) and IDMs. Normal new-
born infants usually undergo one medical procedure in the first
day of life (intramuscular injection of vitamin K), with additional
procedures undertaken as medically necessary. IDMs, on the other
hand, routinely undergo at least 3 (and upwards of 10 or more)
heel lances in addition to vitamin K injection in the first day of life
to monitor blood glucose levels [29]. Other than the tendency to
develop hypoglycemia, which is promptly treated when diagnosed,
these infants are considered healthy and room-in with their moth-
ers on the postnatal ward. We excluded infants that were admitted
to the neonatal intensive care unit, scheduled to undergo circum-
cision during the study period, had a major congenital or neurolog-
ical anomaly, had a clinical diagnosis of birth asphp<ia [1] or
seizures, or were receiving analgesics or sedatives.
All infants were randomized to receive either 2 ml of 24% su-
crose (weight/volume) or 2 ml of sterile water (placebo) by mouth
2 minutes prior to all tissue-damaging needle procedures per-
formed from birth, including the newborn screening test, per-
formed by venipuncture on the dorsum of the hand,
approximately 24 h later. The randomization sequence generation
and concealment of allocation details have been previously pub-
lished [26].
The study was approved by the Research Ethics Boards of
Mount Sinai Hospital, The Hospital for Sick Children, York Univer-
sity and Health Canada, and was conducted on the Mother and
Baby Unit at Mount Sinai Hospital, Toronto, Canada.
The newborn screening test was performed using a venipunc-
ture on the dorsum of the hand rather than a heel lance (the usual
method of blood sampling in newborns in the study centre). This
approach enabled us to assess the presence of hyperalgesia in a re-
mote, uninjured region of the body (i.e., hand) subsequent to re-
peated injury elsewhere on the body. Thus, we tested the
hypothesis that repeated injury would induce a remote hyperalge-
sia to non-inflamed, non-sensitized skin in the hand. We defined
hyperalgesia as an increase in response to venipuncture for infants
exposed to a high number of needle procedures when compared to
a control group ofinfants exposed to a low number ofprocedures.
Venipuncture is also less painful than heel lance [17] and so was
selected to minimize pain in all participants.
All data were collected prospectively in a standardized meth-
od previously described [26]. Infant pain responses were video
recorded during the first tissue-damaging needle procedure after
delivery (intramuscular vitamin I( injection administered on the
anterior aspect of the thigh, within the first hour of life) and
venipuncture for the newborn screening test (administered
approximately 24 h later on the dorsum of the hand). In addi-
tion, infant responses were video recorded during a non-tissue-
damaging handling procedure (i.e., diaper change) performed
within the first hours of life and again after the newborn screen-
ing test. Approximately 5 min prior to each procedure, a portable
pulse oximeter (Datex-Ohmeda 3900P) was applied to the- in-
fant's foot and a digital camera (Sony DCRTRV25) and tripod
were positioned approximately 1m from the infant's body. The
infant's face was videotaped during the entire procedure. Physi-
ological (heart rate and oxygen saturation) responses were also
recorded continuously during the procedure. All procedures were
carried out by certified nurse(s) or physician(s) as per standard
clinical practice.
2.1. Pain outcome measures
We assessed the infants' pain responses to vitamin K injection
and venipuncture using three validated measures ofpain: the Pre-
mature Infant Pain Profile (PIPP) [20], an observer-rated, global
behavioural measure using a 10cm visual analog scale (VAS) for
pain, and cry duration [25]. We assessed infants' responses to dia-
per change using the PIPP.
As previously described [26], the primary outcome was the
PIPP score. The PIPP was developed from pain responses ob-
served in preterm infants and subsequently validated in preterm
and full-term infants [21]. It incorporates three behavioural (fa-
cial actions: brow bulge, eyes squeezed shut, naso-labial furrow),
two physiological (heart rate, oxygen saturation) and two con-
textual (gestational age, infant state) indicators of pain that are
scored individually on a 4-point scale from 0 to 3 and then
summed together for an overall score. A research assistant that
was unaware of treatment allocation, exposure group and study
hypotheses, scored each facial action as present or absent in 2-s
intervals from the videotaped footage for the first 30 s of the
venipuncture (first 20 s of intramuscular injection of vitamin K,
or less if the procedure lasted less than 20 s) using established
methods [21]. The percentage of the total time that each facial
action was observed during each phase was calculated and used
to assign a score of 0-3. For physiologic data, heart rate and oxy-
gen saturation change from baseline was recorded over the same
time frame and used to assign a score of 0-3. A total PIPP score
was computed for each phase of the procedure by summing the
scores of the seven indicators. In full-term infants, PIPP scores
can vary from 0 (no pain) to 18 (maximum pain) [2i]. At pres-
ent, the PIPP is the most commonly used multidimensional mea-
sure of pain in infants and incorporates the indicators of pain
most frequently used.
Secondary measures of pain included a 10 cm VAS for pain with
endpoints labelled "no pain" and "worst possible pain", and total
crying time in seconds, defined as audible sound in the presence
of facial grimacing. VAS pain scores and cry duration were inde-
pendently scored from the videotapes by two other research assis-
tants who were also unaware of treatment allocation, exposure
group, and study hypotheses.
2.2. Statistical analysis
Using Power Analysis and Statistical Software, PASS (NCSS Sta-
tistical Software, I(aysville, Utah), our sample size calculation
determined that 240 infants provided 95% power to detect a differ-
ence of 20% between high and low exposure groups with an inter-
action between exposure and drug treatment groups. For this
analysis, infants were divided into two exposure groups, using
Table 1
characteristics of participating newborn infants.
Values are means (standard deviation, SD) or frequency (percent).
" n = l3l for Premature Infant Pain Profile in infants in low exposure (g4 painful
procedures) group and n=79 for Premature lnfant Pain Profile in infants in high
exposure ( >5 painful procedures) group.
" Student's r-test or f test, as appropriate.
the median cut-off technique, based on the number of painful pro-
cedures they had undergone Ihigh (>5) or low (<4)] prior to the
newborn screening test. Univariate 2-factor ANCOVAs were used
to compare PIPP scores, VAS pain and cry duration scores during
the newborn screening test between exposure groups (high vs.
low number of procedures) and drug treatment groups (sucrose
vs. placebo), adjusting for the baseline pain score during vitamin
K injection.
The number of painful procedures that infants had undergone
prior to venipuncture was correlated with PIPP scores, VAS pain
scores and cry duration during venipuncture (after subtracting
baseline scores during vitamin K injection) using Pearson's r.
Demographic data and baseline PIPP scores, VAS pain scores and
cry duration scores during vitamin K injection were analyzed using
y2 test, or Student's f-test, as appropriate.
In order to rule out the possibility that observed differences be-
tween exposure groups in the pain outcome measures were due to
underlying maternal medical condition (lDMs vs. normal infant)
we compared PIPP scores, VAS pain scores and cry duration be-
tween IDMs and normal infants, adjusting for analgesic treatment
allocation and number of painful procedures.
In order to determine whether exposure-related increases in
pain responses were specific to noxious (tissue-damaging) stimuli
or generalized to non-noxious stimuli as well, we compared infant
PIPP scores during a diaper change performed after the venipunc-
ture using a 2-factor (exposure group and drug treatment group)
ANCOVA, adjusting for baseline diaper change PIPP scores obtained
within the first few hours after birth,
Afl intent-to-treat approach was used that included all infants
where outcome data were obtained. A p value of 0.05 or less was
considered statistically significant. Data were analyzed using SAS
(version 9.1; SAS Institute Inc., Cary, NC).
3. Results
Of 24O infants enrolled in the trial [26], outcome data were
available for 214 (89%) of infants. The remainder (n = 26) were ex-
cluded due to the following circumstances: clinical deterioration
(n = 1 1 ), withdrawal of parental consent (N = 6), procedure missed(n=5), major protocol violation (n=3), and reason not docu-
mented (n = 1).
Using the median cut-off of 4 for the number of procedures
experienced prior to venipuncture for the newborn screening test,
133 infants were assigned to the low exposure group (94 prior
procedures) and 81 were assigned to the high exposure group(25 prior procedures). Twenty-seven (2O%) of infants in the low
exposure group, and 80 (99%) of infants in the high exposure group
were IDMs.
Demographic characteristics are shown in Table 1. Infant PIPP
scores, VAS pain scores and cry duration during vitamin K injection
(the first needle procedure performed after birth) did not differ be-
tween groups, indicating that infants were comparable at the very
first painful procedure. The median (range) number ofprocedures
for infants in the low and high exposure groups was 1 (1-4) and 6
(5-13), respectively; p < 0.001. Fig. 1 shows a schematic flow dia-
gram of the timing and frequency of needle procedures in the
low and high exposure groups.
3.1. Pain response during venipuncture for the newborn screening test
Compared to infants in the low exposure group, infants in the
high exposure group had higher PIPP scores [mean (95% Cl): 7.1(6.5-7.8) vs. 8.4 (7.6-9.2)i p = O.O12l and VAS pain scores [2.5 cm(2.1-2.9) vs. 3.2 cm (2.7-3.7); p=0.0471 but not cry duration
scores [25.7 s (18.6-32.9) vs. 33.8 s (24.7-43.0); p =0.7711
(Fig. 2). Pre-treatment with sucrose resulted in lower PIPP [mean
(95% CI): 6.s (s.8-7.2) vs. 9.1 (8.4-9.8); p < 0.00011, VAS pain [1.9(1.4-2.4) vs. 3.8 (33-43); p<0.00011, and cry duration [13.1(5.0-2'1.2) vs. 46.3 (38.2-54.4: p < 0.00011 scores (Fig. 2). There
were no statistically significant interactions between procedure
exposure level and treatment allocation (p=0.742 for PIPP,
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Fig. 1. Schematic flow diagram showing the timing and frequency of needle procedures for the high and low exposure groups. All infants received an intramuscular (lM)
injection ofvitamin K (vit K) into the anterior aspect ofthe thigh a median of0.6 h after birth, The high and low exposure groups underwent a median of6 (range 5-13) and 1
(range 1 
-4) needle puncture procedures, respectively, over the ensuing two days, followed by a venipuncture on the dorsum ofthe hand at a median of 26 h after birth. The
venipuncture was performed in uninjured tissue. The outcomes of interest were the infants' responses to the venipuncture as measured by the PIPP, an observer rated VAS for














Fig 2. Pain responses during Venipuncture for the newborn screening test values
are means (standard error, SE). ANCOVA results:'-PIPP (Premature Infant Pain
Profile) scores: p = O.O72 for exposure group: p < 0.0001 for treatment group. 'VAS
(Visual Analog Scale) pain scores: p=0.047 for exposure group; p<0.0001 for
treatment group. Cry duration: p=0.171 for exposure group; p<0.0001 for
treatment group. For all analyses, n = 133 in low exposure (E4 painful procedures)
group and n = 81 in high exposure ( 25 painful procedures) group; except for PIPP
scores where n = 130 in low exposure group and n = 79 in high exposure group.
p=O.547 for VAS pain scores, and p=0.344 for cry duration,
respectively).
The number of painful procedures was correlated with PIPP
scores (Pearson's r = 0.2, p = 0.004) and VAS pain scores (r = 0.74,
p = 0.044), but not cry duration (r = 0.08, p = 0.238).
Secondary analyses comparing pain responses between IDMs
and normal infants, adjusting for number of painful procedures
and analgesic treatment allocation, did not demonstrate any differ-
ences for any of the outcome measures (p = 0.965 for PIPP scores,
p = 0.277 for VAS pain seores, and p = 0.365 for cry duration). In
addition, there were no significant differences in pain responses
between the IDMs and normal infants within the low exposure
group (p > 0.05 for all analyses).
Secondary analyses comparing PIPP scores in response to a dia-
per change after the venipuncture did not show a significant differ-
ence between the high and low exposure groups nor a significant
interaction between exposure and treatment (sucrose vs. placebo)
groups (p > 0.05 for all analyses). Infants treated with sucrose,
however, had lower PIPP scores than infants treated with placebo
(p < 0.001) [27].
4. Discussion
The present study demonstrates that infants exposed to a high
number (5 or more) of needle puncture procedures in the first day
of life display greater pain responses, as assessed using PIPP and
VAS pain scores, during a subsequent venipuncture performed on
the second day of life when compared with infants exposed to a
low number of procedures. Administration of sucrose prior to all
painful procedures reduced scores during the venipuncture at
24 h, However, infants who experienced more frequent procedures
had higher scores despite pre-treatment with sucrose.
This is the first study to evaluate the combined effects of cumu-
lative exposure to tissue-damaging procedures and repeated su-
crose administration on remote hyperalgesia in full-term infants.
The results are consistent with our previous study demonstrating
that IDMs have a heightened pain response to venipuncture when
compared to normal infants [25]. In that study, IDMs had under-
gone an average of 10 additional painful heel lance procedures
compared to normal infants. In the present study, we demon-
strated that five procedures are sufficient for newborn infants to
develop hyperalgesia to a subsequent venipuncture. The threshold
for inducing increased behavioural responsiveness to painful pro-
cedures in neonates is likely close to five procedures given that
in a previous study, three heel lances failed to result in a noticeable
change in pain behaviours over time although heart rate increased
with successive procedures [15].
Two decades ago, in the first study ofhyperalgesia in neonates,
Fitzgerald et al. [10] demonstrated that flexor reflex thresholds in
preterrn infants were diminished in an area of inflamed skin due
to previous tissue damage. Thresholds were not, however, altered
in uninjured skin [10]. Subsequently, in the first study ol remote
hyperalgesia in full-term newborn infants, we demonstrated that
male circumcision was associated with an increase in infant pain
responses at 4- and 6-month routine immunization [23]. In a fol-
low-up study, we showed that treatment of circumcision pain with
topical local anaesthesia attenuated these increased responses,
suggesting a protective effect ofanalgesia [24]. The observed inef-
fectiveness of sucrose in preventing hyperalgesia in the present
study may be because it is a relatively weak analgesic, develop-
ment of tolerance occurs after repeated administration, or hyperal-
gesia is mediated by processes that are not influenced by sucrose.
In our effectiveness analysis of the present study, sucrose con-
ferred only a modest (16%) reduction in overall infant pain when
used for all painful procedures [26], consistent with other recently
published data [121. It is possible that this magnitude of pain












and analgesic strategies aimed at preventing rather than decreas-
ing pain, are needed. The lack of effect of sucrose may also depend
on the development of tolerance. However, there was no evidence
of tolerance in our effectiveness analysis [26]. Finally, although the
exact mechanisms by which sucrose exerts its analgesic effects are
not known, it is presumed to activate the endogenous opioid sys-
tem [7]. It is well established that opioids are relatively ineffective
at reducing hyperalgesia associated with the N-methyl-o-aspartate
(NMDAFmediated state of central sensitization that arises after in-jury [30].
The finding that PIPP scores in response to venipuncture, but
not diaper change, were significantly greater in the high vs. low
exposure group suggests that the mechanism underlying the re-
mote hyperalgesia is nociceptive specific. Although we do not
know the precise mechanism underlying the remote hyperalgesia,
we suggest it may involve the absence of endogenous inhibitory
controls in young infants in combination with the stress effects
produced by the hypothalamo-pituitary-adrenocortical and the
sympatho-adreno-medullary systems. It is possible that the stress
response and sympathetic arousal associated with prior tissue-
damaging procedures in the high exposure group induce a wide-
spread sensitization to subsequent C-fiber strength noxious inputs.
The immature descending inhibitory control system in the neonate
would therefore not be capable of mounting an effective counter
response [11] to the excitatory, noxious inputs associated with
the venipuncture, leading to a (spatially) remote hyperalgesia in
the high exposure group.
It is possible that higher PIPP and VAS pain scores observed in
infants exposed to many vs. few procedures may be due to under-
lying differences in the infants (such as altered in-utero environ-
ment associated with the mother's diabetes status in IDMS).
However, infants did not differ in their pain response during veni-
puncture as a function of maternal diabetes status (lDMs vs. nor-
mal) when the number of procedures experienced was accounted
for, suggesting that it is cumulative exposure to procedures that
underlies the development of hyperalgesia rather than the disease.
Additional studies are needed, however, to rule out differences in
pain responses due to underlying medical condition.
These data have implications for clinical practice since proce-
dural pain is commonplace in hospitalized newborn infants [9],
and sucrose has become widely adopted to manage procedural
pain [28]. Based on the observed results, sucrose should not be gi-
ven as the sole analgesic agent for the management of procedural
pain in newborn infants undergoing repeated painful procedures.
Additional research on the effects of multiple analgesic strategies
combined together is needed.
There are several strengths of our study including inclusion of
healthy full-term newborn infants which reduced the confounding
effects of underlying medical condition or development on assess-
ments of pain [6]; double-blind, randomized design for drug
administration, minimizing bias; venipuncture pedormed in previ-
ously uninjured site thus avoiding the confounding effects of
inflammation and hyperalgesia induced by repeated procedures
[10]; and use of multiple validated measures of pain with a consis-
tent paftern of results, increasing confidence in the interpretation.
In addition, the study results are generalizable to a large infant pop-
ulation due to the inclusion of IDMs and normal infants. and the use
of multiple nurses and physicians performing medical procedures.
In conclusion, newborn infants exposed to five or more tissue-
damaging needle procedures over the first two days of life had
higher pain responses, as assessed using the PIPP and VAS pain
scores, during a subsequent venipuncture for the newborn screen-
ing test than infants exposed to four or fewer tissue-damaging nee-
dle procedures. Consistent use of sucrose for all procedures did not
prevent the development of hyperalgesia to venipuncture. These
results point to the need to: (i) minimize tissue-damaging needle
procedures in the newborn period and, (ii) develop safe and effec-
tive agents to prevent pain and the development of hyperalgesia
following multiple painful procedures.
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